BioCentury | Apr 17, 2021
Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...analysis to detect residual disease.Relay buying machine learning company ZebiAIPrecision oncology and genetic diseases company Relay Therapeutics Inc....
...3-kinase mTOR (FRAP) (RAFT1) - Mammalian target of rapamycin BC Staff gedatolisib (PF-05212384, pki-587) Lumicks B.V. Molecular Assemblies Inc. Celcuity Inc. Surrozen Inc. Relay Therapeutics Inc. C2i...
BioCentury | Feb 25, 2021
Finance

Foresite raises nearly $1B to back data science plays with fifth fund, incubator

...convergence of data science, machine learning and drug discovery,” said Foresite’s Michael Rome, who cited Relay Therapeutics Inc....
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...BRAF and FGFR2/3 mutants in preclinical development. Relay Therapeutics Inc....
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

...AlphaFold because the structures were there,” said Relay Therapeutics Inc....
...– Interleukin-2 receptor alpha chain Karen Tkach Tuzman Alphabet Inc. Relay Therapeutics Inc. Neoleukin...
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

...with its $487.3 million offering in June. Relay Therapeutics Inc....
BioCentury | Dec 15, 2020
Deals

Genentech gets competitive in KRAS with early dealmaking push: Data Byte

...unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered with Relay Therapeutics Inc....
...Src homology protein tyrosine phosphatase 2 Lauren Martz RLY-1971 Genentech Inc. Relay Therapeutics Inc. KRAS...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...IPOs for cancer companies delivered postmoney valuations in the $1.7 billion range. Precision oncology play Relay Therapeutics Inc....
BioCentury | Jul 18, 2020
Finance

Biotech trio’s NASDAQ debuts push year’s IPO haul past $13B

...fifth of a warrant redeemable at $11.50 The series of offerings came the day after Relay Therapeutics Inc....
BioCentury | Jul 16, 2020
Finance

Relay’s IPO among the year’s largest for a biotech as others wait in wings

...FGF) receptor 2 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Relay Therapeutics Inc. ALX...
BioCentury | Jul 9, 2020
Finance

Poseida prices $224M IPO as two other biotechs eye listings of similar size

...and the price range earlier in the day from a prior proposal. A third biotech, Relay Therapeutics Inc....
...in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta Inc. Relay Therapeutics Inc. Inventiva...
Items per page:
1 - 10 of 37
BioCentury | Apr 17, 2021
Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...analysis to detect residual disease.Relay buying machine learning company ZebiAIPrecision oncology and genetic diseases company Relay Therapeutics Inc....
...3-kinase mTOR (FRAP) (RAFT1) - Mammalian target of rapamycin BC Staff gedatolisib (PF-05212384, pki-587) Lumicks B.V. Molecular Assemblies Inc. Celcuity Inc. Surrozen Inc. Relay Therapeutics Inc. C2i...
BioCentury | Feb 25, 2021
Finance

Foresite raises nearly $1B to back data science plays with fifth fund, incubator

...convergence of data science, machine learning and drug discovery,” said Foresite’s Michael Rome, who cited Relay Therapeutics Inc....
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...BRAF and FGFR2/3 mutants in preclinical development. Relay Therapeutics Inc....
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

...AlphaFold because the structures were there,” said Relay Therapeutics Inc....
...– Interleukin-2 receptor alpha chain Karen Tkach Tuzman Alphabet Inc. Relay Therapeutics Inc. Neoleukin...
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

...with its $487.3 million offering in June. Relay Therapeutics Inc....
BioCentury | Dec 15, 2020
Deals

Genentech gets competitive in KRAS with early dealmaking push: Data Byte

...unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered with Relay Therapeutics Inc....
...Src homology protein tyrosine phosphatase 2 Lauren Martz RLY-1971 Genentech Inc. Relay Therapeutics Inc. KRAS...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...IPOs for cancer companies delivered postmoney valuations in the $1.7 billion range. Precision oncology play Relay Therapeutics Inc....
BioCentury | Jul 18, 2020
Finance

Biotech trio’s NASDAQ debuts push year’s IPO haul past $13B

...fifth of a warrant redeemable at $11.50 The series of offerings came the day after Relay Therapeutics Inc....
BioCentury | Jul 16, 2020
Finance

Relay’s IPO among the year’s largest for a biotech as others wait in wings

...FGF) receptor 2 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Relay Therapeutics Inc. ALX...
BioCentury | Jul 9, 2020
Finance

Poseida prices $224M IPO as two other biotechs eye listings of similar size

...and the price range earlier in the day from a prior proposal. A third biotech, Relay Therapeutics Inc....
...in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta Inc. Relay Therapeutics Inc. Inventiva...
Items per page:
1 - 10 of 37